Provectus Biopharmaceuticals, Inc.

Warrants SEC Reporting - Current
Verified Company Profile 10/04/2017
Contact Info
  • 10025 Investment Drive
  • Suite 250
  • Knoxville, TN 37932

Business Description

Financial Reporting/Disclosure
Reporting Status U.S. Reporting: SEC Reporting
Audited Financials Audited
Latest Report Sep 30, 2017 10-Q
CIK 0000315545
Fiscal Year End 12/31
OTC Marketplace OTCQB
Profile Data
SIC - Industry Classification 2834 - Pharmaceutical preparations
Incorporated In: DE, USA
Year of Inc. 2002
Employees 2 a/o Apr 28, 2017
Company Officers/Contacts
Timothy C. Scott, Ph.D. President, Principal Executive Officer
Eric Wachter, Ph.D. CTO
Company Directors
Dominic Rodrigues Chairman
Bruce Horowitz
Jan E. Koe
Eric Wachter, Ph.D.
Company Notes
  • Formerly=Provectus Pharmaceutical, Inc. until 1-2014
  • Formerly=Zamage Digital Imaging, Inc. until 4-02
  • Note=4-1-02 State of Incorporation Colorado changed to Nevada
  • Note=12-31-04 company is in the development stage
  • Formerly=SPM Group, Inc. until 11-01
Service Providers
Accounting/Auditing Firm
Marcum LLP
750 Third Ave
11th Floor
New York, NY, 10017
United States

Legal Counsel
Baker Donelson Bearman Caldwell & Berkowitz
211 Commerce Street
Suite 800
Nashville, TN, 37201
United States

Investor Relations Firm
Not Available
PVCTW Security Details Other Company Securities
Share Structure
Market Value1 $569,647 a/o Dec 15, 2017
Authorized Shares 28,482,344 a/o Jun 30, 2016
Outstanding Shares 28,482,344 a/o Jun 30, 2016
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float Not Available
Par Value Not Available
Transfer Agent(s)
Shareholders of Record Not Available
Short Selling Data
Short Interest 2,780 (0%)
Nov 15, 2017
Significant Failures to Deliver No

1Market Value calculated only for respective security